BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

866 related articles for article (PubMed ID: 25388687)

  • 1. Zinc finger nuclease-mediated gene knockout results in loss of transport activity for P-glycoprotein, BCRP, and MRP2 in Caco-2 cells.
    Sampson KE; Brinker A; Pratt J; Venkatraman N; Xiao Y; Blasberg J; Steiner T; Bourner M; Thompson DC
    Drug Metab Dispos; 2015 Feb; 43(2):199-207. PubMed ID: 25388687
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A new intestinal cell culture model to discriminate the relative contribution of P-gp and BCRP on transport of substrates such as imatinib.
    Graber-Maier A; Gutmann H; Drewe J
    Mol Pharm; 2010 Oct; 7(5):1618-28. PubMed ID: 20701289
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential selectivity of efflux transporter inhibitors in Caco-2 and MDCK-MDR1 monolayers: a strategy to assess the interaction of a new chemical entity with P-gp, BCRP, and MRP2.
    Mease K; Sane R; Podila L; Taub ME
    J Pharm Sci; 2012 May; 101(5):1888-97. PubMed ID: 22359351
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regulation of expression and activity of multidrug resistance proteins MRP2 and MDR1 by estrogenic compounds in Caco-2 cells. Role in prevention of xenobiotic-induced cytotoxicity.
    Arias A; Rigalli JP; Villanueva SS; Ruiz ML; Luquita MG; Perdomo VG; Vore M; Catania VA; Mottino AD
    Toxicology; 2014 Jun; 320():46-55. PubMed ID: 24685904
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Small intestinal efflux mediated by MRP2 and BCRP shifts sulfasalazine intestinal permeability from high to low, enabling its colonic targeting.
    Dahan A; Amidon GL
    Am J Physiol Gastrointest Liver Physiol; 2009 Aug; 297(2):G371-7. PubMed ID: 19541926
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of efflux transporters on the transport of highly toxic aconitine, mesaconitine, hypaconitine, and their hydrolysates, as determined in cultured Caco-2 and transfected MDCKII cells.
    Ye L; Yang X; Yang Z; Gao S; Yin T; Liu W; Wang F; Hu M; Liu Z
    Toxicol Lett; 2013 Feb; 216(2-3):86-99. PubMed ID: 23200901
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of Drug Transport in MDCKII-Wild Type, MDCKII-MDR1, MDCKII-BCRP and Caco-2 Cell Lines.
    Mukkavilli R; Jadhav G; Vangala S
    Curr Pharm Biotechnol; 2017; 18(14):1151-1158. PubMed ID: 29521222
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High-activity p-glycoprotein, multidrug resistance protein 2, and breast cancer resistance protein membrane vesicles prepared from transiently transfected human embryonic kidney 293-epstein-barr virus nuclear antigen cells.
    Karlsson JE; Heddle C; Rozkov A; Rotticci-Mulder J; Tuvesson O; Hilgendorf C; Andersson TB
    Drug Metab Dispos; 2010 Apr; 38(4):705-14. PubMed ID: 20071452
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aristolochic acid I is a substrate of BCRP but not P-glycoprotein or MRP2.
    Ma L; Qin Y; Shen Z; Bi H; Hu H; Huang M; Zhou H; Yu L; Jiang H; Zeng S
    J Ethnopharmacol; 2015 Aug; 172():430-5. PubMed ID: 26183576
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of efflux transporters involved in distribution and disposition of apixaban.
    Zhang D; He K; Herbst JJ; Kolb J; Shou W; Wang L; Balimane PV; Han YH; Gan J; Frost CE; Humphreys WG
    Drug Metab Dispos; 2013 Apr; 41(4):827-35. PubMed ID: 23382458
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interaction Studies of Resolvin E1 Analog (RX-10045) with Efflux Transporters.
    Cholkar K; Trinh HM; Vadlapudi AD; Wang Z; Pal D; Mitra AK
    J Ocul Pharmacol Ther; 2015 May; 31(4):248-55. PubMed ID: 25844889
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Roles of P-glycoprotein, Bcrp, and Mrp2 in biliary excretion of spiramycin in mice.
    Tian X; Li J; Zamek-Gliszczynski MJ; Bridges AS; Zhang P; Patel NJ; Raub TJ; Pollack GM; Brouwer KL
    Antimicrob Agents Chemother; 2007 Sep; 51(9):3230-4. PubMed ID: 17576841
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reversal of different drug-resistant phenotypes by an autocatalytic multitarget multiribozyme directed against the transcripts of the ABC transporters MDR1/P-gp, MRP2, and BCRP.
    Kowalski P; Surowiak P; Lage H
    Mol Ther; 2005 Apr; 11(4):508-22. PubMed ID: 15771954
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Silencing the breast cancer resistance protein expression and function in caco-2 cells using lentiviral vector-based short hairpin RNA.
    Zhang W; Li J; Allen SM; Weiskircher EA; Huang Y; George RA; Fong RG; Owen A; Hidalgo IJ
    Drug Metab Dispos; 2009 Apr; 37(4):737-44. PubMed ID: 19131524
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genomic Knockout of Endogenous Canine P-Glycoprotein in Wild-Type, Human P-Glycoprotein and Human BCRP Transfected MDCKII Cell Lines by Zinc Finger Nucleases.
    Gartzke D; Delzer J; Laplanche L; Uchida Y; Hoshi Y; Tachikawa M; Terasaki T; Sydor J; Fricker G
    Pharm Res; 2015 Jun; 32(6):2060-71. PubMed ID: 25522789
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibitory potential of tuberculosis drugs on ATP-binding cassette drug transporters.
    Te Brake LH; Russel FG; van den Heuvel JJ; de Knegt GJ; de Steenwinkel JE; Burger DM; Aarnoutse RE; Koenderink JB
    Tuberculosis (Edinb); 2016 Jan; 96():150-7. PubMed ID: 26682943
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel understanding of ABC transporters ABCB1/MDR/P-glycoprotein, ABCC2/MRP2, and ABCG2/BCRP in colorectal pathophysiology.
    Andersen V; Svenningsen K; Knudsen LA; Hansen AK; Holmskov U; Stensballe A; Vogel U
    World J Gastroenterol; 2015 Nov; 21(41):11862-76. PubMed ID: 26557010
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Application and limitation of inhibitors in drug-transporter interactions studies.
    Wang Q; Strab R; Kardos P; Ferguson C; Li J; Owen A; Hidalgo IJ
    Int J Pharm; 2008 May; 356(1-2):12-8. PubMed ID: 18272304
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization and Validation of Canine P-Glycoprotein-Deficient MDCK II Cell Lines for Efflux Substrate Screening.
    Ye D; Harder A; Fang Z; Weinheimer M; Laplanche L; Mezler M
    Pharm Res; 2020 Sep; 37(10):194. PubMed ID: 32918191
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of aripiprazole and its active metabolite dehydroaripiprazole on the activities of drug efflux transporters expressed both in the intestine and at the blood-brain barrier.
    Nagasaka Y; Oda K; Iwatsubo T; Kawamura A; Usui T
    Biopharm Drug Dispos; 2012 Sep; 33(6):304-15. PubMed ID: 22847220
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 44.